The Epilepsy Foundation Eastern PA is dedicated to improving the quality of life for people with epilepsy. This mission includes funding research initiatives that seek to treat and prevent epilepsy in patients.
With the help of “Julia’s Angels”, a Summer Stroll team, the EFEPA provides annual funding to support research through the Epilepsy Foundation of America and its partnerships, such as the Epilepsy Research Foundation, a partnership of the Epilepsy Foundation and the Epilepsy Therapy Development Project. In the past 5 years, Julia’s Angels and the EFEPA have raised nearly $50,000 for research for a cure.
The Epilepsy Foundation Eastern PA recognizes the world-class research institutions and scientists in Pennsylvania, and attempts to support their initiatives. In addition, we recognize that we need to encourage more young people to take an interest in neurology, and the national research program has done an exceptional job of bringing young researchers into the field.
Currently, Epilepsy research is in need of more funding. Although epilepsy is more prevalent than autism, multiple sclerosis, and Parkinson’s combined it receives less funding per patient.
Participate in Research
Treatments cannot advance without clinical trials. Clinical trials are necessary to test the effectiveness of new therapies and to develop better ways of using known treatments. In some cases, they can make the difference between life and death for patients or a significantly improved quality of life.
About 1 in 3 individuals taking anti-seizure medication still have seizures, and others get unwanted side effects. Thus, those individuals with epilepsy are in a special position to help others through participating in medical research that can lead to effective treatments.
Participating in a clinical trial, however, is a significant commitment and one should always have a good understanding about the study and clinical trials in general before any agreement is made.
The National Institute of Health’s website will help you gain a broad understanding of clinical trials. Learn possible benefits and pitfalls of clinical trials, what questions you should ask before participating, as well as the fundamental steps involved in clinical experiments.
We provide access to two lists of current research studies in epilepsy recruiting volunteers: clinicaltrials.gov and CenterWatch.
These lists represent only a small amount of epilepsy studies seeking volunteers. To find out about other studies, you can look for advertisements in newspapers or trade journals. Your own health care provider may be conducting research for which you are eligible or may know of other studies looking for volunteers. If you do a search on the internet, you will find that many medical sites have email lists you can join to be notified of available studies.
Pregnant women with epilepsy who are taking antiepileptic drugs can help researchers learn how certain drugs affect unborn children by participating in the Antiepileptic Drug Pregnancy Registry.
The Antiepilepsy Drug (AED) Pregnancy Registry is the first North American registry for pregnant women who are taking anti-epileptic drugs. The registry is maintained out of Genetics and Teratology Unit of Massachusetts General Hospital in Boston. Women who enroll will be asked to provide information about the health status of their children. (All information will be kept confidential.) The findings will be analyzed to assess the fetal risk of AED use during pregnancy. The principal investigator for the registry is Lewis B. Holmes, M.D.
Women and physicians are urged to call the registry directly at the toll-free number, (888) 233-2334. For further information on the registry, please contact Massachusetts General Hospital — (617) 726-1742 or visit their website at http://www2.massgeneral.org/aed/
The following are current studies that are being conducted. Participate in epilepsy research and help to develop improved treatments and find a cure!
Study to Investigate Safety of Drugs Topiramate and Levetiracetam in treating Children Recently Diagnosed with Epilepsy
The purpose of this study is to evaluate the safety of topiramate monotherapy compared with levetiracetam another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy (seizure disorder) on pediatric growth and maturation, bone mineralization, and kidney stone formation in children aged 2 to 15 years.. Visit the study’s clinicaltrials.gov page for more information.
The Human Epilepsy Project (HEP)
HEP is a five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy. Men and woman ages 12 to 60 years are eligible. For more information visit https://clinicaltrials.gov. Contact: Sabrina Cristofaro, email@example.com.
Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy (KD)
The goal of the present open label study is to obtain pilot data to evaluate the efficacy and safety of KD in adults with intractable epilepsy. This will be an open label study comparing seizure frequency during 4 months of prospective baseline observation period with seizure frequency during 4 months of add-on KD treatment. 18-65 year old men and women with refractory epilepsy, defined as seizures persisting in spite of past/present treatments with ≥ 3 AEDs, with seizure frequency of ≥ 0.5/month, will be evaluated. Eligible participants must have had epilepsy for at least 2 years prior to enrollment. The program is sponsored by the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland. View the study page here.
Phase 3 Study of Adjunctive Ganaxolone in Adults with Drug-Resistant, Partial Onset Seizures
The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, ganaxolone, on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs). Click here for more information about the trial.
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy
The purpose of this proof-of-concept study is to evaluate ganaxolone as adjunctive therapy for uncontrolled seizures in female children with PCDH19 mutations. After establishing baseline seizure frequency, qualifying subjects will enter the study and be treated with open-label ganaxolone for up to six months. For more information about the trial, click here.
Epilepsy Birth Control Registry
Despite the importance of birth control to women of reproductive age, there has been little formal investigation of the safety and effectiveness of birth control methods in women with epilepsy. To remedy this, doctors from Harvard and Columbia University Medical Schools have developed a website that offers a survey to help us gain more knowledge and some educational material that will be updated regularly to provide the latest information. The ultimate goal is to develop guidelines for the selection of safe and effective birth control methods and to make sure that the best forms of birth control become available to women with epilepsy in all communities of our society. Go to www.epilepsybirthcontrolregistry.com, take the survey and then catch up on the latest information about birth control for women with epilepsy.
Epilepsy Phenome/Genome Project
The Epilepsy Phenome/Genome Project (EPGP) is the largest research study ever created to identify genes that influence epilepsy and genes that affect an individual’s response to seizure medications. The National Institutes of Health is partnering with major epilepsy centers around the country in order to understand what causes epilepsy, which treatment will be effective, and why some families have multiple relatives with seizures. For more information, please contact EPGP at toll-free phone: 1-888-279-EPGP, website: www.epgp.org, or e-mail: firstname.lastname@example.org. This program is active but not recruiting.
Evaluation and Treatment of Patients With Epilepsy
This study has three purposes: 1) to screen patients with seizures for participation in research studies of NINDS’s Clinical Epilepsy Section (CES), 2) to follow the natural course of seizure disorders and 3) to train CES fellows in evaluating and treating epilepsy. Only standard diagnostic tests and treatments will be used in this study. Patients of any age with seizures who are referred to CES may participate in this study. At the end of the study, patients may be discharged to the care of their referring physician, offered participation in another NINDS research study, or followed for teaching purposes. Contact Patient Recruitment and Public Liaison Office at NIH (800) 411-1222 email@example.com.
Family Studies in Epilepsy
Under the direction of David A. Greenberg, PhD, at Columbia University, this research is being conducted to determine the causes of inherited forms of epilepsy. Study participation takes less than two hours and includes completion of the consent form, family interviews to collect clinical history and a saliva sample from each participant. For more information, call 212-342-0481 or visit the study website www.geneticsofepilepsy.org.
Genetics of Severe Early Onset Epilepsies
Investigators at Boston Children’s Hospital are conducting research in order to better understand the genetic factors which may contribute to disorders related to epilepsy. These findings may help explain the broad spectrum of clinical characteristics and outcomes seen in people with epilepsy. Click here to view the full study details.
For more information on clinical trials visit http://www.clinicaltrials.gov/ct2/results?term=epilepsy
*This listing of epilepsy studies is for information purposes only; and the reader assumes full responsibility and risk for the appropriate use of the information provided. The information concerning the study was sent to the Epilepsy Foundation Eastern PA by the investigator or staff conducting the research. The Epilepsy Foundation, its affiliates, officers, directors, employees and agents do not warrant or guarantee the accuracy or completeness of this information and specifically disclaims any liability therefore.